½ÃÀ庸°í¼­
»óǰÄÚµå
1424384

¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå : ¾à¹° À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 240¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2030³â 20¾ï 3,470¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç ¿¹Ãø ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 7.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2022³â 2023/2024³â ½ÃÀå ±Ô¸ð 12¾ï240¸¸ ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018³â-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø±â°£ 2023³â/2024³â-2030³â/2031³â º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR): 7.80% 2030/2031³â °¡Ä¡ ¿¹Ãø 20¾ï 3,470¸¸ ´Þ·¯
±×¸² 1. ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå Á¡À¯À²(%), Áö¿ªº°(2023³â)
Anti-Epileptic Drugs for Pediatrics Market-IMG1

°£ÁúÀº ¼¼°è ¸ðµç ¿¬·É´ëÀÇ »ç¶÷µéÀÌ ¾Î°íÀÖ´Â ÀϹÝÀûÀÎ ½Å°æ ÁúȯÀÔ´Ï´Ù. ±×·¯³ª °£ÁúȯÀÚÀÇ 70% °¡±îÀ̰¡ ¼ºÀÎÀÌ µÇ±â Àü¿¡ Áø´ÜµÇ±â ¶§¹®¿¡ ¼Ò¾Æ¿¡ º¸´Ù ¸¹ÀÌ º¸ÀÔ´Ï´Ù. Ç× °£Áú ¾à¹°Àº °£Áú ¹ßÀÛÀ» °ü¸®ÇÏ°í °£Áú·Î °íÅë¹Þ´Â ¼Ò¾Æ ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¾à¹°Àº ³ú¿¡¼­ ºñÁ¤»óÀûÀÎ ½Å°æ ¼¼Æ÷ÀÇ ¹ßÈ­¿Í µ¿±âÈ­¸¦ Á¦¾îÇÏ¿© ¹ßÀÛÀ» ¿¹¹æÇÔÀ¸·Î½á È¿°ú¸¦ ¹ßÈÖÇÕ´Ï´Ù. ÃÖ±Ù, ±¤¹üÀ§ÇÑ Á¶»ç°³¹ß¿¡ ÀÇÇØ ¼Ò¾Æ¿ë Ç×°£Áú¾àÀ¸·Î¼­ º¸´Ù À¯È¿ÇÏ°í ºÎÀÛ¿ëÀÌ ÀûÀº ½Å¼¼´ë Ç×°£Áú¾àÀÌ °³¹ß¡¤½ÂÀεǾú½À´Ï´Ù. À̰ÍÀº ¼Ò¾Æ °£Áú ȯÀÚÀÇ º¹¿ë º¸Çè°ú Ä¡·á ¼ºÀû¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ¼Ò¾Æ °£ÁúÀÇ ¿øÀÎÀº ¿Ü»ó, Ãâ»ý½Ã ÇÕº´Áõ, À¯Àü Áúȯ µîÀÔ´Ï´Ù. ¼ö¸·¿°°ú °°Àº ³ú °¨¿°À¸·Î ÀÎÇØ ¹ßº´ÇÏ´Â °£ÁúÀ» ÁõÈļº °£ÁúÀ̶ó°í Çϸç, À¯Àü°ú °ü·ÃµÈ ÁúȯÀ» Ư¹ß¼º °£ÁúÀ̶ó°í ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀåÀº ¼Ò¾Æ °£ÁúÀ¯º´·ü Áõ°¡¿¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é °£ÁúÀº ¼¼°è ¼Ò¾ÆÀÇ ¾à 1%°¡ º´À» ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡ ÀÇ·áºñ Áõ°¡, °£Áú Ä¡·á¿¡ ´ëÇÑ ÀǽÄÀÇ ³ô¾ÆÁü, »õ·Î¿î Ç×°£Áú¾àÀÇ µµÀÔ µîÀÇ ¿äÀÎÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå °³Ã´¿¡ µå´Â ºñ¿ëÀÇ ³ôÀ̳ª ¼Ò¾Æ¿ë ÀǾàǰÀÇ ½ÂÀο¡ °üÇÑ ±ÔÁ¦ÀÇ ¾ö°ÝÇÔ µî ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀεµ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç× °£Áú ¾à¹°ÀÇ ¼Ò¾Æ ½Å°æ°è¿¡ ´ëÇÑ ºÎÀÛ¿ëÀÌ °úÁ¦°¡µÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, Áúº´ °³Áú ¿ä¹ýÀÇ ¿¬±¸°³¹ß°ú °³ÀÎÈ­µÈ Ç×°£Áú¾à ¿ä¹ýÀÇ °³¹ßÀº ÇâÈÄ ½ÃÀå Âü°¡Àڵ鿡°Ô ÁÖ¸ñÇÒ ¸¸ÇÑ ±âȸÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023³â-2030³â) ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ¼ºÀå ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ Çà·Ä¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûµµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ µû¶ó ÇÁ·ÎÆÄÀÏÇϰí ÀÖ½À´Ï´Ù.
  • º» Á¶»çÀÇ ´ë»óÀÌ µÇ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â »ç³ëÇÇ, ¿¡ÀÚÀÌ, È­ÀÌÀÚ, UCB SA, »ç³ëºñ¿Â ÆÛ¸Ó½´Æ¼ÄÃÁî, ¾Öº¿, ÀçÁî ÆÛ¸Ó½´Æ¼ÄÃÁî, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., ´ÙÀ̼î Á¦¾à Ȧµù½º, Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd. µîÀÌ Æ÷ÇԵ˴ϴÙ.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× °¢ ±â¾÷ÀÇ °æ¿µÁøÀº ¹Ì·¡ÀÇ Á¦Ç° ½ÃÀå - ŸÀÌÇÎ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, Æ®·»µå ºÐ¼®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • ½Å°æ Àå¾ÖÀÇ ¹ß»ý·ü Áõ°¡
  • ¿¬±¸°³¹ß Ȱµ¿ Áõ°¡
    • ¾ïÁ¦¿äÀÎ
  • ±ÔÁ¦ ´ç±¹¿¡ ÀÇÇÑ Á¦Ç° ¸®ÄÝ Áõ°¡
  • Ç×°£ÁúÁ¦ÀÇ ºÎÀÛ¿ë
    • ½ÃÀå ±âȸ
  • ¹Ì°³¹ß ½ÅÈï ½ÃÀå
  • Ç¥Àû ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
  • ¿µÇ⠺м®
  • ±ÔÁ¦ °¡À̵å¶óÀÎ
  • Á¦Ç° ¹ß¸Å
  • ÁÖ¿ä °³¹ß
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÇÕº´°ú Àμö
  • Á¦Á¶¾÷ü ¼öÀÍ
  • ±¹°¡º° °Ç°­ °ü¸® ÁöÃâ

Á¦4Àå ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå-½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿µÇ⠺м®

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎÀÇ ´ëó
  • COVID-19¿¡ ÀÇÇÑ ½ÃÀå¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå - ¾àÁ¦ À¯Çüº°(2018³â-2030³â)

  • Á¦1¼¼´ë Ç×°£Áú¾à
  • Á¦2¼¼´ë Ç×°£Áú¾à
  • Á¦3¼¼´ë Ç×°£Áú¾à

Á¦6Àå ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå - Åõ¿© °æ·Îº°(2018³â-2030³â)

  • °æ±¸
  • ÁÖ»ç °¡´É
  • ±âŸ(ÄÚ µî)

Á¦7Àå ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå - À¯Åë ä³Îº°(2018³â-2030³â)

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°è ¼Ò¾Æ¿ë Ç×°£Áú¾à ½ÃÀå - Áö¿ªº°(2018³â-2030³â)

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Sanofi
  • Eisai Co., Ltd.
  • Pfizer Inc.
    • Company Highlight
  • UCB SA
    • Company Highlight
  • Sunovion Pharmaceuticals Inc.
  • Abbott
  • Jazz Pharmaceuticals plc
  • Ovid Therapeutics Inc.
  • SK BIOPHARMACEUTICALS
  • Alexza Pharmaceuticals, Inc.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Marinus Pharmaceuticals, Inc.
  • Xenon Pharmaceuticals Inc.
  • Lundbeck A/S
  • Teva Pharmaceutical Industries Ltd.

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
BJH 24.02.26

The global anti-epileptic drugs for pediatrics market size is expected to reach US$ 2,034.7 Mn by 2030, from US$ 1,202.4 Mn in 2023, exhibiting a compound annual growth rate (CAGR) of 7.8% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023/2024: US$ 1,202.4 Mn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023/2024 to 2030/2031 CAGR: 7.80% 2030/2031 Value Projection: US$ 2,034.7 Mn
Figure 1. Global Anti-epileptic Drugs for Pediatrics Market Share (%), By Region, 2023
Anti-Epileptic Drugs for Pediatrics Market - IMG1

Epilepsy is a common neurological disorder that affects people of all ages globally. However, it is more prevalent in children as almost 70% of epilepsy cases are diagnosed before reaching adulthood. Anti-epileptic drugs play a crucial role in managing seizures and improving quality of life for pediatric patients suffering from epilepsy. These medications work by controlling abnormal neuronal firing and synchrony in the brain to prevent seizures. In recent years, extensive research has led to the development and approval of newer generation anti-epileptic drugs that are more effective and have less side effects than the earlier drugs for pediatric use. This has positively impacted medication adherence and treatment outcomes for children with epilepsy. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while a genetics related condition is called idiopathic epilepsy.

Market Dynamics

The global anti-epileptic drugs for pediatrics market is driven by the growing prevalence of epilepsy among children. According to the World Health Organization (WHO), epilepsy affects around 1% of children worldwide. Besides this, factors such as increasing healthcare expenditures, rising awareness about epilepsy treatment, and introduction of newer anti-epileptic drugs are fueling the market growth. However, the market faces certain restraints such as high costs associated with drug development and stringent regulations for the approval of pediatric drugs. Moreover, adverse effects of anti-epileptic drugs on developing neurological system of children poses challenges. On the positive side, ongoing research on disease modifying therapies and development of personalized anti-epileptic drug regimens present notable opportunities for market players in the future.

Key features of the study:

  • This report provides an in-depth analysis of the global anti-epileptic drugs for pediatrics market, and provides market size (US$ Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anti-epileptic drugs for pediatrics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as part of this study include Sanofi, Eisai Co., Ltd., Pfizer Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Abbott, Jazz Pharmaceuticals plc, Ovid Therapeutics Inc., SK BIOPHARMACEUTICALS, Alexza Pharmaceuticals, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Marinus Pharmaceuticals, Inc., Xenon Pharmaceuticals Inc., H. Lundbeck A/S, and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type upgrade, market expansion, and marketing tactics
  • The global anti-epileptic drugs for pediatrics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-epileptic drugs for pediatrics market

Detailed Segmentation:

  • Global Anti-Epileptic Drugs for Pediatrics Market, Drug Type:
    • First generation anti-epileptic drugs
    • Second generation anti-epileptic drugs
    • Third generation anti-epileptic drugs
  • Global Anti-Epileptic Drugs for Pediatrics Market, Route of Administration:
    • Oral
    • Injectable
    • Others (Nasal, etc.)
  • Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-Epileptic Drugs for Pediatrics Market, By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Company Profiles
    • Sanofi
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • UCB S.A.
    • Sunovion Pharmaceuticals Inc.
    • Abbott
    • Jazz Pharmaceuticals plc
    • Ovid Therapeutics Inc.
    • SK BIOPHARMACEUTICALS
    • Alexza Pharmaceuticals, Inc.
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • Xenon Pharmaceuticals Inc.
    • Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Type
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trend Analysis

  • Market Dynamics
    • Drivers
  • Increasing incidence of neurological disorders
  • Increasing research and development activities
    • Restraints
  • Increasing product recalls by regulatory authorities
  • Side effects of anti-epileptic drugs
    • Market Opportunities
  • Untapped emerging markets
  • The rising demand for targeted therapy
  • Impact Analysis
  • Regulatory Guidelines
  • Product Launches
  • Key Development
  • PEST Analysis
  • PORTER's Analysis
  • Regulatory Scenario
  • Mergers and Acquisitions
  • Manufacturer Revenue
  • Healthcare Spending by Country

4. Global Anti-Epileptic Drugs for Pediatrics Market - COVID-19 Impact Analysis

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Anti-Epileptic Drugs for Pediatrics Market, By Drug Type, 2018-2030, (US$ Mn)

  • Overview
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • First generation anti-epileptic drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Second generation anti-epileptic drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Third generation anti-epileptic drugs
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

6. Global Anti-Epileptic Drugs for Pediatrics Market, By Route of Administration, 2018-2030, (US$ Mn)

  • Overview
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Injectable
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Others (Nasal, etc.)
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

7. Global Anti-Epileptic Drugs for Pediatrics Market, By Distribution Channel, 2018-2030, (US$ Mn)

  • Overview
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Anti-Epileptic Drugs for Pediatrics Market, By Region, 2018-2030, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018- 2030, (US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer Inc.
    • Company Highlight
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • UCB S.A.
    • Company Highlight
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sunovion Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Abbott
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Jazz Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ovid Therapeutics Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • SK BIOPHARMACEUTICALS
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Alexza Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Taisho Pharmaceutical Holdings Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Marinus Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Xenon Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Lundbeck A/S
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦